Nov 27, 2017   SOURCE: PR NewsWire

Global $51.3 Bn Women's Health Market Analysis 2014-2017 & 2025

DUBLIN, November 27, 2017 /PRNewswire/ --

The "Women's Health Market Analysis By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome), By Region, And Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global women's health market is expected to reach USD 51.3 billion by 2025

Further Key Findings From the Report Suggest:

    --  Presence of a large female geriatric population, which is susceptible to
        chronic diseases, is expected to boost growth
    --  In 2016, postmenopausal osteoporosis accounted for the largest share of
        the market due to high incidence of osteoporosis in women after
        menopause, presence of several major players, and cost-effectiveness of
        this treatment
    --  Contraceptive segment is likely to witness fastest growth during the
        forecast period due to increase in awareness and usage, government
        initiatives, technological developments, and favorable regulatory
        scenario. For instance, in June 2017, Agile Therapeutics, Inc.
        resubmitted an NDA for Twirla, an investigational low-dose combined
        hormonal contraceptive patch
    --  Geographically, North America held the largest share of more than 30% in
        2016 due to presence of major market players, high awareness about
        regular health check-ups for women, coverage for screening, and
        increased healthcare expenditure
    --  Asia Pacific is expected to exhibit fastest growth during the forecast
        period due to increasing investments by players in the region, rising
        awareness about women's health, and initiatives by various governments
        and private organizations to improve awareness and access to women's
        health products

    --  Some of the key players operating in the women's health market are
        Allergan; Bayer AG; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical
        Industries Ltd.; Agile Therapeutics; Amgen, Inc.; AstraZeneca;
        Bristol-Myers Squibb Company; and Ferring B.V.

Increasing female geriatric population, introduction of various drugs related to women's health, and favorable government policies are some of the factors expected to drive growth during the forecast period.

Women are more prone to certain diseases, such as osteoporosis, osteoarthritis, anemia, menstruation-related disorders, depression, and obesity. Hence, increase in incidence of these conditions is likely to boost the market in the coming years. According to International Osteoporosis Foundation, global prevalence of osteoporosis among women was over 200.0 million in 1990, and this is anticipated to reach 680.0 million in 2050.

Government and various private organizations are working toward improving women's health across the world, and this is likely to drive growth in the coming years. Reimbursement coverage provided to women is also a key factor driving the market in developed countries. For instance, various coverage plans in the U.S. provide preventive services for women without charging any copayment. These include screening for anemia, hepatitis B, & breast cancer on a routine basis, folic acid supplements for women who are likely to be pregnant, and contraceptive methods, among others.

Key Topics Covered:

Chapter 1. Research Methodology

Chapter 2. Executive Summary

Chapter 3. Women's Health Market Variables, Trends & Scope

Chapter 4. Women's Health Market: Drug Estimates & Trend Analysis

Chapter 5. Women's Health Market: Application Estimates & Trend Analysis

Chapter 6. Women's Health Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape 

    --  Allergan
    --  Bayer AG
    --  Merck & Co., Inc.
    --  Pfizer, Inc.
    --  Teva Pharmaceutical Industries Ltd.
    --  Agile Therapeutics
    --  Amgen, Inc.
    --  Apothecus Pharmaceutical Corporation
    --  AstraZeneca
    --  Blairex Laboratories, Inc.
    --  Bristol-Myers Squibb Company
    --  Ferring B.V.

For more information about this report visit https://www.researchandmarkets.com/research/57k866/womens_health

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-513-bn-womens-health-market-analysis-2014-2017--2025-300561846.html

SOURCE Research and Markets